Origen Therapeutic's goal is to develop chickens that produce fully human monoclonal and polyclonal antibodies. To achieve this aim the chicken Origen needs the capability to insert and modify the chicken genome and to transmit these genomic modifications through the germline. Origen's platform centers around a cell based system that allows integration of large pieces of DNA and allows precise deletions in the genome. To this end Origen has identified a cell population that has the potential to enter the germline. This application focuses on transfecting this cell population with large (150 kb) constructs and to knock-out specific genes within the chicken genome. These transfected cell popupations will then be trafficked through the germline to obtain a flock of transgenic chickens. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44GM073306-02
Application #
7054360
Study Section
Special Emphasis Panel (ZRG1-BDA-B (15))
Program Officer
Portnoy, Matthew
Project Start
2005-03-01
Project End
2008-05-31
Budget Start
2006-06-05
Budget End
2007-05-31
Support Year
2
Fiscal Year
2006
Total Cost
$631,309
Indirect Cost
Name
Origen Therapeutics
Department
Type
DUNS #
026167994
City
Emeryville
State
CA
Country
United States
Zip Code
94608
Leighton, Philip A; van de Lavoir, Marie-Cecile; Diamond, Jennifer H et al. (2008) Genetic modification of primordial germ cells by gene trapping, gene targeting, and phiC31 integrase. Mol Reprod Dev 75:1163-75